异隐丹参酮对胃癌细胞增殖、周期和凋亡的影响

摘要/Abstract

摘要： 目的探讨异隐丹参酮（ICTS）对胃癌BGC-823和SGC-7901细胞增殖、周期、凋亡的影响及可能机制。方法体外培养胃癌细胞系BGC-823、SGC-7901，采用0、5、10、20 μmol／L ICTS处理24、48、72 h后， CCK-8法检测细胞的增殖抑制率；确定ICTS抑制BGC-823和SGC-7901细胞的最佳浓度和最佳作用时间后，流式细胞术检测其细胞周期和凋亡率。Western blotting检测ICTS处理后胃癌细胞中Cyclin D1、Bcl-2、p53、p21蛋白的表达。结果 0、5、10、20 μmol／L ICTS处理BGC-823细胞24 h的增殖抑制率分别为（0.789±0.048）％、（16.74±1.55）％、（33.58±2.26）％、（54.62±2.61）％，差异具有统计学意义（P＜0.05）；0、5、10、20 μmol／L ICTS 处理SGC-7901细胞24 h的增殖抑制率分别为（-0.184±0.023）％、（12.76±1.73）％、（32.95±2.47）％、（53.80±2.65）％，差异具有统计学意义（P＜0.05）。20 μmol／L ICTS 处理BGC-823细胞24、48、72 h的增殖抑制率分别为（54.62±2.61）％、（55.08±2.35）％、（59.72±2.53）％，差异无统计学意义（P＞0.05）；20 μmol／L ICTS 处理SGC-7901细胞24、48、72 h的增殖抑制率分别为（53.80±2.65）％、（55.76±2.47）％、（61.83±2.82）％，差异无统计学意义（P＞0.05）。20 μmol／L ICTS处理BGC-823、SGC-7901细胞24 h后G0／G1期细胞比例为（78.34±7.13）％和（79.57±7.34）％，均高于对照组，差异具有统计学意义（P＜0.05）。ICTS处理组BGC-823、SGC-7901凋亡率分别为（24.78±3.42）％和（28.76±4.21）％，均高于对照组，差异具有统计学意义（P＜0.05）。20 μmol／L ICTS处理BGC-823、SGC-7901细胞24 h后Cyclin D1和Bcl-2蛋白表达量均显著低于对照组，差异有统计学意义（P＜0.05）；p53和p21蛋白表达量显著高于对照组，差异有统计学意义（P＜0.05）。结论 ICTS通过增加p53、p21表达，降低Cyclin D1和Bcl-2表达，进而抑制细胞增殖，增加细胞G0／G1阻滞和凋亡，发挥抗胃癌的作用。

关键词: 胃癌, 异隐丹参酮, 增殖, 凋亡

Abstract:

Objective Effects of isocryptotanshinone （ICTS） on proliferation， cycle and apoptosis of gastric cancer cell lines BGC-823 and SGC-7901 and its possible mechanism. Methods Gastric cancer cell lines BGC-823 and SGC-7901 were cultured in vitro. After treatment of 0，5，10，20 μmol／L ICTS for 24， 48 and 72 hours， CCK-8 method was used to detect the inhibition rate of cell proliferation. After determining the optimal concentration and time of ICTS inhibiting BGC-823 and SGC-7901 cells， cell cycle and apoptotic rate were detected by flow cytometry. Western blotting was used to detect the expression of Cyclin D1， Bcl-2， p53 and p21 proteins in gastric cancer cells treated with ICTS. Results The inhibition rates of BGC-823 cells treated with 0，5，10，20 μmol／L ICTS for 24 hours were （0.789±0.048）％，（16.74±1.55）％，（33.58±2.26）％ and （54.62±2.61）％. The difference was statistically significant （P＜0.05）. The inhibition rates of SGC-7901 cells treated with 0，5，10，20 μmol／L ICTS for 24 hours were （-0.184±0.023）％，（12.76±1.73）％，（32.95±2.47）％ and （53.80±2.65）％. The difference was statistically significant （P＜0.05）. The inhibition rates of BGC-823 cells treated with 20 μmol／L ICTS at 24， 48 and 72 hours were （54.62±2.61）％，（55.08±2.35）％，（59.72±2.53）％. There was no significant difference （P＞0.05）. The inhibition rates of SGC-7901 cells treated with 20 μmol／L ICTS at 24， 48 and 72 hours were （53.80±2.65）％，（55.76±2.47）％ and （61.83±2.82）％，. There was no significant difference （P＞0.05）. BGC-823 and SGC-7901 cells were treated with 20 μmol／L ICTS for 24 hours. The percentage of G0／G1 phase cells was （78.34±7.13）％ and （79.57±7.34）％， which were higher than those of the control group（P＜0.05）. The apoptotic rates of BGC-823 and SGC-7901 in ICTS treatment group were （24.78±3.42）％ and （28.76±4.21）％， which were higher than those of control group （P＜0.05）. The expression of Cyclin D1 and Bcl-2 protein in ICTS treatment group was significantly lower than that in the control group （P＜0.05）， and the expression of p53 and p21 protein in ICTS treatment group was significantly higher than that in the control group （P＜0.05）. Conclusion ICTS plays an anti-gastric cancer role by increasing the expression of p53 and p21， reducing the expression of Cyclin D1 and Bcl-2， thereby inhibiting cell proliferation， increasing G0／G1 blockade and apoptosis.

Key words:

Gastric cancer')">"> Gastric cancer, Isocryptotanshinone（ICTS）, Proliferation, Apoptosis

中图分类号:

R735.2

何家杰, 李敏, 唐国富, 李厚泽, 綦晓龙.

异隐丹参酮对胃癌细胞增殖、周期和凋亡的影响 [J]. 临床肿瘤学杂志, 2019, 24(2): 129-132.

HE Jiajie, LI Min, TANG Guofu, LI Houze, QI Xiaolong..

Effects of isocryptotanshinone on proliferation， cycle and apoptosis of gastric cancer cells [J]. Chinese Clinical Oncology, 2019, 24(2): 129-132.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[2]	白秀丽¹，马振刚¹，李际君². 紫杉醇联合卡培他滨治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(1): 68 .
[3]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[4]	鲍永仪¹，关乃富¹，程羽青¹. 小细胞肺癌组织中柯萨奇-腺病毒受体阳性表达的意义[J]. 临床肿瘤学杂志, 2009, 14(2): 176 .
[5]	韩　宇^1，2，王　岩¹，徐建明¹，刘烈军¹，赵传华¹，李志强¹，刘建芝¹，邱　卉¹. 诱导化疗后吉非替尼维持治疗晚期非小细胞肺癌的临床研究[J]. 临床肿瘤学杂志, 2009, 14(2): 118 .
[6]	李美洲¹，刘江惠²，郭建文^１，左连富^２. Ｓｕｒｖｉｖｉｎ和ＰＴＥＮ在脂溢性角化病中的表达及其意义[J]. 临床肿瘤学杂志, 2009, 14(2): 157 .
[7]	朱　川¹，李　刚¹，任必勇¹，刘必宽¹，邓　超¹，张　军¹，张　力¹，刘学芬¹，熊德明¹. 紫杉醇为主联合化疗方案治疗晚期头颈部肿瘤[J]. 临床肿瘤学杂志, 2009, 14(2): 166 .
[8]	张百红¹，王湘辉¹，凌昌全². ＣＩＳ分期系统对预测肝癌预后的价值研究[J]. 临床肿瘤学杂志, 2009, 14(2): 162 .
[9]	单慧敏¹，陈　琳¹，杨其六¹. 甲状腺微小乳头状癌的临床病理分析[J]. 临床肿瘤学杂志, 2009, 14(2): 170 .
[10]	俞　晶¹，黄云超²，张丽娟³，卢玉波¹. ＨＩＦ-１α和ＧＬＵＴ-１在卵巢癌中的表达及临床意义[J]. 临床肿瘤学杂志, 2009, 14(3): 207 .